{
  "ticker": "LLY",
  "target_date": "2025-09-18",
  "actual_date": "2025-09-18",
  "collected_at": "2025-12-08T12:17:54.269059",
  "price": {
    "open": 760.26,
    "high": 771.41,
    "low": 757.9,
    "close": 761.8112182617188,
    "volume": 3464000,
    "change_1d_pct": 0.37,
    "change_7d_pct": 1.64,
    "change_30d_pct": 2.44
  },
  "technicals": {
    "rsi_14": 67.65,
    "sma_20": 738.23,
    "sma_50": 738.63,
    "macd": 9.671,
    "macd_signal": 6.005,
    "macd_histogram": 3.666,
    "bb_upper": 775.18,
    "bb_lower": 701.27,
    "price_vs_sma20_pct": 3.19,
    "price_vs_sma50_pct": 3.14,
    "volume_ratio": 1.03
  },
  "fundamentals": {
    "market_cap": 892512960512,
    "pe_ratio": 48.780045,
    "forward_pe": 43.936485,
    "price_to_book": 37.484966,
    "price_to_sales": 15.020464,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 660.43,
      "change_1d_pct": 0.47,
      "change_7d_pct": 1.54
    },
    "vix": {
      "level": 15.7,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.1
    },
    "dollar_index": {
      "level": 97.35
    },
    "gold": {
      "price": 3643.7
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts",
      "source": "Yahoo",
      "datetime": 1758227110,
      "summary": "VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on riva",
      "url": "https://finnhub.io/api/news?id=5e08b82565b0a1bb6623261e788267c0034a2bf1b044a253ef0b24cf6f887a7a"
    },
    {
      "headline": "Novo Nordisk Surges as Ozempic Beats Lilly's Trulicity",
      "source": "Yahoo",
      "datetime": 1758223999,
      "summary": "Real-world study shows fewer heart attacks, strokes, and deaths",
      "url": "https://finnhub.io/api/news?id=d5b9ab4da81f60b50e66714fcaea4198c744909f4ef630b89130c1f163f8f8a7"
    },
    {
      "headline": "Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents",
      "source": "Yahoo",
      "datetime": 1758217205,
      "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company announced that its diabetes medication, Mounjaro, delivered positive results in Phase 3 Trials in children and adolescents with type 2 diabetes. The diabetes medication reporte",
      "url": "https://finnhub.io/api/news?id=65c3bac828020f707e8aa61604dbfd15d422604910408a0310a3ae1809d6c5a3"
    },
    {
      "headline": "Berenberg Upgrades Novo Nordisk (NVO) Amid Renewed Growth Outlook",
      "source": "Yahoo",
      "datetime": 1758217202,
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg upgraded Novo Nordisk from \u2018Hold\u2019 to \u2018Buy\u2019, and revised its price target to DKK425.00, signaling a potential 20% upside. The move comes after a series of guidance downgrades that ",
      "url": "https://finnhub.io/api/news?id=fb6ccc18a3127ecfba4e332a4fe9ceaa9947e73aeb0ff6088a6d30b2941f8059"
    },
    {
      "headline": "Health Care Roundup: Market Talk",
      "source": "Yahoo",
      "datetime": 1758197100,
      "summary": "HEALTH NEWS  The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0737 GMT \u2013 Roche\u2019s acquisition of 89bio adds a potential blockbuster to its drug pipeline, Vontobel\u2019s Stefan Schneider writes.",
      "url": "https://finnhub.io/api/news?id=a1531e672eb3cbb12f6dd2a48146b9854246edfd090e2fdd147080abb2f56c1d"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142037.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000240/xslF345X05/wk-form4_1758142037.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758141956.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000131021525000005/xslF345X05/wk-form4_1758141956.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}